[
  {
    "ts": "2025-09-29T18:53:58+00:00",
    "headline": "Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most undervalued NASDAQ stocks to buy now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported on September 17 that its experimental medicine garetosmab has met the primary endpoint in a phase 3 trial for adults with fibrodysplasia ossificans progressiva, a rare genetic condition in which muscles, tendons, and ligaments gradually convert […]",
    "url": "https://finance.yahoo.com/news/regeneron-regn-gains-attention-successful-185358969.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ae52775c-ff35-3fb1-91c7-7ab843e286c1",
      "content": {
        "id": "ae52775c-ff35-3fb1-91c7-7ab843e286c1",
        "contentType": "STORY",
        "title": "Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease",
        "description": "",
        "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most undervalued NASDAQ stocks to buy now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported on September 17 that its experimental medicine garetosmab has met the primary endpoint in a phase 3 trial for adults with fibrodysplasia ossificans progressiva, a rare genetic condition in which muscles, tendons, and ligaments gradually convert […]",
        "pubDate": "2025-09-29T18:53:58Z",
        "displayTime": "2025-09-29T18:53:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/2bd5e87846463f859176bc5389ecb5ec",
          "originalWidth": 610,
          "originalHeight": 335,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6NW7XOB2HZ0YvMk7T1pIWg--~B/aD0zMzU7dz02MTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/2bd5e87846463f859176bc5389ecb5ec.cf.webp",
              "width": 610,
              "height": 335,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QBMNU9De4fup9c_Isxs4sw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/2bd5e87846463f859176bc5389ecb5ec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-regn-gains-attention-successful-185358969.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-regn-gains-attention-successful-185358969.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-29T14:43:14+00:00",
    "headline": "Here’s Why Regeneron Pharmaceuticals (REGN) Fell in Q2",
    "summary": "Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. A copy of the letter can be downloaded here. Global equity markets experienced a significant shift during the quarter, moving from notable losses to reaching […]",
    "url": "https://finance.yahoo.com/news/why-regeneron-pharmaceuticals-regn-fell-144314931.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "2d559428-f899-3dae-95b6-22cf5a591425",
      "content": {
        "id": "2d559428-f899-3dae-95b6-22cf5a591425",
        "contentType": "STORY",
        "title": "Here’s Why Regeneron Pharmaceuticals (REGN) Fell in Q2",
        "description": "",
        "summary": "Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. A copy of the letter can be downloaded here. Global equity markets experienced a significant shift during the quarter, moving from notable losses to reaching […]",
        "pubDate": "2025-09-29T14:43:14Z",
        "displayTime": "2025-09-29T14:43:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/bae404889492a528436e130b89e988f3",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4XvGkE05c1FDaEm_fduC7A--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bae404889492a528436e130b89e988f3.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4sASLMl5PQRRQwnFbb40bw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bae404889492a528436e130b89e988f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-regeneron-pharmaceuticals-regn-fell-144314931.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-regeneron-pharmaceuticals-regn-fell-144314931.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-29T12:28:00+00:00",
    "headline": "FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza",
    "summary": "Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.",
    "url": "https://finance.yahoo.com/news/fda-approves-label-extension-regns-122800803.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "0677b1b8-3850-3d5c-8fce-33c24e05300f",
      "content": {
        "id": "0677b1b8-3850-3d5c-8fce-33c24e05300f",
        "contentType": "STORY",
        "title": "FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza",
        "description": "",
        "summary": "Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.",
        "pubDate": "2025-09-29T12:28:00Z",
        "displayTime": "2025-09-29T12:28:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d7sHwZPFV1U3B4BGoNlXfg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k5CBlnqEqKxZI1S0BuG_ug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-label-extension-regns-122800803.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-label-extension-regns-122800803.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-29T10:02:17+00:00",
    "headline": "Regeneron’s Evkeeza gains FDA approval for young HoFH patients",
    "summary": "The decision to broaden the antibody’s indication was based on clinical efficacy and safety data from six children.",
    "url": "https://www.pharmaceutical-technology.com/news/regeneron-evkeeza-hofh/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "94f0b10f-4151-3720-ae39-f2fcc9d1077d",
      "content": {
        "id": "94f0b10f-4151-3720-ae39-f2fcc9d1077d",
        "contentType": "STORY",
        "title": "Regeneron’s Evkeeza gains FDA approval for young HoFH patients",
        "description": "",
        "summary": "The decision to broaden the antibody’s indication was based on clinical efficacy and safety data from six children.",
        "pubDate": "2025-09-29T10:02:17Z",
        "displayTime": "2025-09-29T10:02:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/7404970800b145a427d87bc37caaaa47",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "The antibody was invented leveraging the VelocImmune technology of Regeneron. Credit: Piotr Swat/Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A22YL2l.599pdK0jF_tKnA--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/7404970800b145a427d87bc37caaaa47.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2_GqJ15pKkB2chWpDrFDJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/7404970800b145a427d87bc37caaaa47.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/regeneron-evkeeza-hofh/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-evkeeza-gains-fda-approval-100217188.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-29T04:36:03+00:00",
    "headline": "1 Healthcare Stock with Exciting Potential and 2 We Ignore",
    "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 18.3% gain.",
    "url": "https://finance.yahoo.com/news/1-healthcare-stock-exciting-potential-043603043.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "dbbdea42-f28d-3b84-b122-db9db1f36b71",
      "content": {
        "id": "dbbdea42-f28d-3b84-b122-db9db1f36b71",
        "contentType": "STORY",
        "title": "1 Healthcare Stock with Exciting Potential and 2 We Ignore",
        "description": "",
        "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 18.3% gain.",
        "pubDate": "2025-09-29T04:36:03Z",
        "displayTime": "2025-09-29T04:36:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "REGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E5YeVaDzgHlFxvDwMx9gpg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6HLp77Q1Eazwpb8zaGf6Xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-healthcare-stock-exciting-potential-043603043.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-healthcare-stock-exciting-potential-043603043.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVTY"
            },
            {
              "symbol": "MEDP"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]